TransMedics price target raised to $170 from $120 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on TransMedics to $170 from $120 and keeps an Overweight rating on the shares. Over the last several years, shares of TransMedics have seen a meaningful push to the upside, albeit with some volatility, as investors get comfortable with the large runway Transmedics has in its end market, Piper says. The firm believes the stock is a consensus long at present, though with the entry of more competitors and devices, it acknowledges an ongoing debate around the name.